AXIM Biotechnologies, Inc. (AXIM)

OTCMKTS: AXIM · Delayed Price · USD
0.0118
+0.0003 (2.61%)
Apr 10, 2024, 2:26 PM EDT - Market closed
Market Cap 2.92M
Revenue (ttm) 34,468
Net Income (ttm) -7.22M
Shares Out 237.65M
EPS (ttm) -0.03
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 44,897
Open 0.0116
Previous Close 0.0115
Day's Range 0.0115 - 0.0124
52-Week Range 0.0100 - 0.0550
Beta 1.40
Analysts n/a
Price Target n/a
Earnings Date n/a

About AXIM

AXIM Biotechnologies, Inc. develops and sells diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, and other diseases. The company is developing tests for dye eye diseases; SARS-CoV-2 neutralizing antibody tests; and fentanyl neutralizing antibody tests. It also developing a line of novel diagnostics for early cancer detection, response to treatment, and recurrence monitoring. The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. w... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 6
Stock Exchange OTCMKTS
Ticker Symbol AXIM
Full Company Profile

Financial Performance

In 2022, AXIM's revenue was $8,875, a decrease of -85.32% compared to the previous year's $60,460. Losses were -$5.96 million, -63.94% less than in 2021.

Financial Statements

News

VIDEO: AXIM Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024

Company CEO John Huemoeller II Interviewed by Tony Noto on AXIM's Diagnostic Research Programs in Dry Eye Disease and Parkinson's

17 days ago - GlobeNewsWire

AXIM® Biotechnologies' Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation

The Company's Commercialization Partner Verséa Ophthalmic Places Re-stock Order of AXIM's Digital Assay Reader SAN DIEGO, CA, Feb. 20, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire –  AXIM Biotechnologies...

7 weeks ago - GlobeNewsWire

AXIM® Biotechnologies Partners With Leading Diagnostic Manufacturer Auer Precision to Scale Assay Production

Leading Diagnostic Healthcare Company Signs Contract Manufacturing Agreement in Order to Fulfill Sales of IgE and Lactoferrin DED Diagnostic Assays

4 months ago - GlobeNewsWire

AXIM® Biotechnologies Develops First Non-Invasive, Rapid, Point-of-Care, Diagnostic Test for Parkinson's Disease

SAN DIEGO,--(BUSINESS WIRE)--AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today t...

7 months ago - Business Wire

AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody Test

SAN DIEGO--(BUSINESS WIRE)--AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today th...

9 months ago - Business Wire

Update: AXIM® Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide

Leading Diagnostic Healthcare Company Also Announces Over 50 Initial Clinic Commitments for Its Full Diagnostic Assay Platform

9 months ago - GlobeNewsWire

AXIM® Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide

Leading Diagnostic Healthcare Company Also Announces Over 50 Initial Clinic Commitments for Its Full Diagnostic Assay Platform

9 months ago - GlobeNewsWire

AXIM Biotechnologies Announces Over 40 Initial Clinic Commitments for Its Full Diagnostic Assay Platform Launch

Leading Dry Eye Disease Diagnostic Healthcare Company's Assays to be Performed in Over 40 Initial Clinics Across US SAN DIEGO, CA, May 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire –   AXIM Biotechnol...

11 months ago - GlobeNewsWire

AXIM® Biotechnologies Appoints Kurt Phinney as Chief Operating Officer to Drive Scaling and Optimization of Manufacturing Unit

Leading Diagnostic Healthcare Company Selects Accomplished Operations Executive to Spearhead Growth of Diagnostic Assays Manufacturing

11 months ago - GlobeNewsWire

AXIM® Biotechnologies Commences Commercial Manufacturing of FDA-Cleared Proprietary Ocular Diagnostic Assays

Leading Diagnostic Healthcare Company Begins Manufacturing of Ocular Immunoglobulin (IgE), Lactoferrin Tests to Fulfill Orders From Commercialization Partner

1 year ago - GlobeNewsWire

AXIM® Biotechnologies Files Provisional Patent on Novel Methodology for Use in Optical Diagnostic Assay Manufacturing

Leading Diagnostic Healthcare Company Announces Provisional Patent Filing on Proprietary Use of Materials for Ophthalmological Test Strip Manufacturing

1 year ago - GlobeNewsWire

AXIM® Biotechnologies CEO Issues Letter to Shareholders; Reminds of Conference Call

Summary: In 2022, AXIM® finalized optimization of its R&D and manufacturing infrastructure to be used in its diagnostic program AXIM will continue to generate revenue from its two FDA-cleared dry eye ...

1 year ago - PRNewsWire

AXIM® Biotechnologies Develops Novel Dual IgE/MMP-9 Rapid Ophthalmological Diagnostic Test; Files Provisional Patent

Leading Diagnostic Healthcare Company Announces Development of and Provisional Patent Filing on First-of-Its-Kind Point-of-Care Ophthalmological Diagnostic Solution Enabling Precision Treatment of Com...

1 year ago - GlobeNewsWire

AXIM Biotechnologies Commercial Partner Verséa Ophthalmics Highlights Benefits of AXIM's Eye Diagnostic Solutions

Technology and Benefits Company At Forefront of Leading Ophthalmological Media Outlets' Coverage of Innovative Diagnostic Solutions Technology and Benefits Company At Forefront of Leading Ophthalmolog...

1 year ago - GlobeNewsWire

AXIM® Biotechnologies Receives Initial Order for Diagnostic Solutions as Exclusive Partner Verséa Ophthalmics Commences Initial Commercial Launch

Healthcare Solutions Company Receives Initial Order for Ophthalmic Diagnostic Tests and Readers, Marking First Large Revenue Generating Order for Company Healthcare Solutions Company Receives Initial ...

1 year ago - GlobeNewsWire

AXIM® Biotechnologies Point-of-Care Diagnostic Test Platform Sales Commence With Verséa Ophthalmics' Commercial Launch at AAO 2022

Sales of Point-of-Care Diagnostic Tests for Ocular Surface Disease Commence at the American Academy of Ophthalmology Annual Meeting Through Exclusive Partnership Sales of Point-of-Care Diagnostic Test...

1 year ago - GlobeNewsWire

AXIM® Biotechnologies Signs Exclusive Global Commercialization Agreement With Verséa™ Ophthalmics for Distribution and Sales of Novel Ophthalmic Diagnostics Solutions

Under the Agreement the Company will Sell and Distribute Globally AXIM's Readers and Three Novel Proprietary Tests Designed for Diagnosis of Dry Eye Disease Under the Agreement the Company will Sell a...

1 year ago - GlobeNewsWire

AXIM Biotechnologies Enhances IgE Testing Capabilities; Responds to Global Warming's Impact on Allergy Season

SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface ...

1 year ago - GlobeNewsWire

AXIM Biotechnologies Celebrates Feature on the Vision is More Than 20/20™ Podcast

SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface ...

1 year ago - GlobeNewsWire

AXIM Biotechnologies Publishes Study Highlighting Neutralizing Antibody Levels of Poor Vaccine Responders with a Third COVID-19 Vaccine Dose

SAN DIEGO, July 12, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company, announced today their pub...

1 year ago - GlobeNewsWire

AXIM Launches New Eye Care Website; Establishes Platform for Commercialization

SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface d...

2 years ago - GlobeNewsWire

AXIM Biotechnologies Completes Optimization of Only FDA-Cleared IgE Rapid Diagnostics Test – In-House Manufacturing Lowers Cost and Eliminates Supply Chain Expenditures

SAN DIEGO, May 24, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface di...

2 years ago - GlobeNewsWire

AXIM Biotechnologies Develops Novel Tear Sample Collector System, Files Patent Application

SAN DIEGO, May 10, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc ( OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye disease...

2 years ago - GlobeNewsWire

AXIM Develops Quantitative Rapid Diagnostic Test for Lacritin; Now Boasts Four Dry Eye Disease Point-of-Care Biomarker Tests

SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting Dry Eye Dise...

2 years ago - GlobeNewsWire

AXIM Biotechnologies CEO Issues Letter to Shareholders

AXIM places strategic focus on commercializing FDA-cleared Dry Eye Disease (DED) diagnostic system

2 years ago - GlobeNewsWire